Method for enhancing the oxygenation level of tissue cells as an alternative method for hyperbaric oxygen therapy

Patent metadata

Field	Value
Publication number	US-9937150-B2
Application number	US-201615071186-A
Country	US
Kind code	B2
Filing date	Mar 15, 2016
Priority date	Mar 15, 2016
Publication date	Apr 10, 2018
Grant date	Apr 10, 2018

Abstract

The present invention relates to a method for substituting for or acting with the hyperbaric oxygen therapy to improve hypoxia, comprising the step of: administrating a phthalide compound to a subject in need thereof, wherein the phthalide compound can increase the oxygen release efficiency of blood hemoglobin (Hb) in the subject and further increase the cellular oxygenation level, and when the phthalide compound substitutes for or act with the hyperbaric oxygen therapy, the common adverse side effects of the hyperbaric oxygen therapy, such as barotrauma, decompression sickness and oxygen poisoning, are prevented. The phthalide compound is used to substitute for or act with 2,3-BPG, to modulate and decrease the oxygen affinity of hemoglobin (Hb), to increase the oxygen release efficiency of hemoglobin (Hb) to tissue cells, thereby achieving a normal cellular oxygenation level and maintaining the cellular oxygenation level in a normal range.

First claim

What is claimed is:

1. A method for substituting for or acting with a hyperbaric oxygen therapy (HBOT) to treat hypoxia, comprising the step of: administering a phthalide compound in combination with 2,3-bisphosphorglycerate to a subject in need thereof to increase oxygen release efficiency of hemoglobin (Hb) in the subject, wherein the subject is a subject treated by the hyperbaric oxygen therapy or a subject who needs to be treated by the hyperbaric oxygen therapy, wherein the phthalide compound is selected from the group consisting of Z-butylidenephthalide, Z-ligustilide, senkyunolide A, senkyunolide H, senkyunolide I, senkyunolide F, E-butylidenephthalide, E-ligustilide, 3-butylphthalide, 3-butylidene-4-hydrophthalide, 6,7-dihydroxyligustilide and 6,7-epoxyligustilide.

2. The method of claim 1 , wherein the phthalide compound provides a synergistic effect with the 2,3-bisphosphorglycerate in the subject on increasing the oxygen release efficiency of hemoglobin (Hb).

3. The method of claim 1 , wherein methods for administering the drug comprises oral administration, injection or inhalation of aerosolized medication.

Assignees

• National Sun Yat Sen University

Inventors

• Wang Chia-Chen
• Chen Wei-Ren

Classifications

• A61K31/683

  Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols · CPC title

• A61K31/365 Primary

  Lactones · CPC title

• A61K31/6615

  Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid · CPC title